BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 177 filers reported holding BLUEBIRD BIO INC in Q4 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $177,000 | -58.3% | 36,500 | -13.9% | 0.00% | -33.3% |
Q4 2021 | $424,000 | -55.8% | 42,400 | -15.5% | 0.00% | -70.0% |
Q3 2021 | $959,000 | -34.0% | 50,200 | +10.6% | 0.01% | -28.6% |
Q2 2021 | $1,452,000 | +9.4% | 45,400 | +3.2% | 0.01% | +7.7% |
Q1 2021 | $1,327,000 | +33.9% | 44,000 | +92.1% | 0.01% | +30.0% |
Q4 2020 | $991,000 | +17.0% | 22,900 | +45.9% | 0.01% | 0.0% |
Q3 2020 | $847,000 | +101.2% | 15,700 | +127.5% | 0.01% | +100.0% |
Q2 2020 | $421,000 | +38.9% | 6,900 | +4.5% | 0.01% | +25.0% |
Q1 2020 | $303,000 | -50.7% | 6,600 | -5.7% | 0.00% | -42.9% |
Q4 2019 | $614,000 | +63.3% | 7,000 | +70.7% | 0.01% | +75.0% |
Q3 2019 | $376,000 | -38.5% | 4,100 | -14.6% | 0.00% | -42.9% |
Q2 2019 | $611,000 | -31.9% | 4,800 | -15.8% | 0.01% | -36.4% |
Q1 2019 | $897,000 | +110.1% | 5,700 | +32.6% | 0.01% | +83.3% |
Q4 2018 | $427,000 | -36.5% | 4,300 | -6.5% | 0.01% | -25.0% |
Q3 2018 | $672,000 | -16.0% | 4,600 | -9.8% | 0.01% | -20.0% |
Q2 2018 | $800,000 | – | 5,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
Summit X, LLC | 103,424 | $651,000 | 0.19% |